Jane Street’s BioXcel Therapeutics BTAI Stock Holding History

Jane Street’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,075	Closed	-$97.9K	–	9222
2023 Q4	$97.9K	Buy	2,075 +606	+41%	+$33.7K	﹤0.01%	8587
2023 Q3	$59.5K	Sell	1,469 -3,581	-71%	-$362K	﹤0.01%	8114
2023 Q2	$538K	Buy	5,050 +3,762	+292%	+$1.25M	﹤0.01%	6206
2023 Q1	$384K	Buy	+1,288	New	+$550K	﹤0.01%	6781
2021 Q3	–	Sell	-463	Closed	-$215K	–	9942
2021 Q2	$215K	Buy	+463	New	+$252K	﹤0.01%	8698
2021 Q1	–	Sell	-1,969	Closed	-$1.46M	–	9102
2020 Q4	$1.46M	Sell	1,969 -100	-5%	-$77.9K	﹤0.01%	4054
2020 Q3	$1.44M	Sell	2,069 -2,550	-55%	-$1.91M	﹤0.01%	3531
2020 Q2	$3.92M	Buy	+4,619	New	+$3.01M	﹤0.01%	2148

Other funds holding BTAI

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Jane Street's BTAI Position: Q1 2026 in Review

Jane Street sold out of BioXcel Therapeutics (BTAI) in Q1 2026, closing a stake of 127,501 shares — an estimated $204K sold.

Jane Street first reported a position in BTAI in Q1 2020 and held it in 18 quarters. The position peaked at $3.15M in Q3 2020. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

Jane Street reported no remaining BioXcel Therapeutics position as of Q1 2026 after selling out during the quarter.
Jane Street sold 127,501 BioXcel Therapeutics shares in Q1 2026, an estimated $204K.
Jane Street first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 18 quarters.
Jane Street's BioXcel Therapeutics position peaked at $3.15M in Q3 2020.
40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.